Catalyst Dossier · compiled by CeliA 🧫
Basel Medical Group Ltd (BMGL)
Services-Offices & Clinics of Doctors of Medicine · market cap $12M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-03-15 (est.)
Phase 3
Pipeline
18
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2027-03-15 (est.)Phase 3 · Colchicineimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PQR309 | Phase 2 | Lymphoma |
| LSD | Phase 2 | Major Depressive Disorder |
| Paclitaxel dosing according to SmPC | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Interferon beta-1b group | Phase 2 | Relapsing-remitting Multiple Sclerosis |
| Interferon beta 1b | Phase 2 | Multiple Sclerosis |
| Vortioxetine | Phase 2 | Glioblastoma |
| CHILD-IVITAB | Phase 2 | Scabies |
| Dapansutrile | Phase 2 | Diabetes Mellitus, Type 2 |
| Cinacalcet | Phase 2 | Memory Functions |
| Salbutamol | Phase 2 | Memory Functions |
| Colchicine | Phase 3 | Atrial Fibrillation |
| Fampridine SR | Phase 2 | Working Memory |
| High-dose influenza vaccine | Phase 3 | Influenza |
| Vitamin D3 | Phase 3 | Improve Healthy Ageing in Seniors; Prevent Disease at Older Age |
| Conestat alfa | Phase 2 | Acute Kidney Injury |
| High ribavirin dose | Phase 2 | Chronic Hepatitis C |
| Celestamine® | Phase 3 | Community-acquired Pneumonia |
| N-TEC | Phase 2 | Patellofemoral Osteoarthritis |
Price & technical context
3-month
-64.6%
6-month
-85.1%
12-month
—
52-wk range
$0.70–$6.08
vs 50-day MA
-48.6%
vs 200-day MA
-73.4%
Realized vol
271.7%
Max drawdown
-88.5%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BMGL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.